BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/20/2026 7:08:28 AM | Browse: 3 | Download: 7
 |
Received |
|
2026-01-07 03:45 |
|
Peer-Review Started |
|
2026-01-07 03:46 |
|
First Decision by Editorial Office Director |
|
2026-01-28 08:40 |
|
Return for Revision |
|
2026-01-28 08:40 |
|
Revised |
|
2026-02-07 10:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-13 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-13 09:50 |
|
Articles in Press |
|
2026-04-13 09:50 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-06 02:58 |
|
Publish the Manuscript Online |
|
2026-07-20 07:08 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nikolaos Ktenopoulos, Nikias Milaras, Anastasios Apostolos, Konstantinos Tsioufis, Konstantinos Toutouzas and Skevos Sideris |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nikias Milaras, MD, First Department of Cardiology, “Hippokration“ General Hospital, National and Kapodistrian University of Athens, Vasilisis Sofias 14, Athens 11527, Greece. nikiasmilaras@gmail.com |
| Key Words |
Hypertensive emergencies; Coronary artery disease; Nitroglycerin; Labetalol; Intravenous antihypertensive therapy; Myocardial ischemia |
| Core Tip |
Chaudhary et al provide large real-world evidence in coronary artery disease-associated hypertensive emergency comparing intravenous nitroglycerin with labetalol. Labetalol achieved target blood pressure faster, but nitroglycerin produced greater blood pressure reduction, fewer bradycardic events, smaller biomarker rises, shorter intensive care unit/hospital stays, and fewer 30-day readmissions. These results support phenotype-driven therapy, that labetalol when heart rate control is paramount, and nitroglycerin when ischemia, pulmonary congestion or myocardial injury risk dominate. Prospective validation is required before practice-changing recommendations. |
| Publish Date |
2026-07-20 07:08 |
| Citation |
Ktenopoulos N, Milaras N, Apostolos A, Tsioufis K, Toutouzas K, Sideris S. Letter to the Editor: Reassessing intravenous antihypertensive choice in coronary artery disease-related hypertensive emergencies. World J Cardiol 2026; 18(7): 118635
|
| URL |
https://www.wjgnet.com/1949-8462/full/v18/i7/118635.htm |
| DOI |
https://doi.org/10.4330/wjc.118635 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
